The Plasmodium sporozoite survives RTS,S vaccination.
The outcome of the Phase IIb trial of RTS,S (a vaccine comprising the polypeptides RTS and S) in young Mozambican children consolidated hopes that effective vaccination against malaria is a step nearer, and even elicited a generous promise of commitment from the Chancellor of the Exchequer of the UK. However, it seems that both optimism and generosity should be moderated by the failure of this vaccine to induce meaningful protection against infection by Plasmodium falciparum and that we should await confirmation of its efficacy in diminishing the incidence of severe malaria.
Snounou
Georges
G
Equipe Parasitologie Comparée et Modèles Expérimentaux, USM0307, CNRS IFR101, Muséum National d'Histoire Naturelle, CP52, 61 Rue Buffon, 75231 Paris Cedex 05, France. snounou@mnhn.fr
Grüner
Anne Charlotte
AC
Müller-Graf
Christine D M
CD
Mazier
Dominique
D
Rénia
Laurent
L
D000818:Animals; D004912:Erythrocytes / Q000469:parasitology; D006801:Humans; D008018:Life Cycle Stages; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D034101:Sporozoites / Q000276:immunology*; D016896:Treatment Outcome
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins